After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a result—a condition that impacts 6.8 million Americans and carries a high ...

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

One year after receiving CRISPR gene editing therapy at CHOP, a Delaware County baby is thriving, and doctors want to expand treatment to others.

Turning genes on and off is like flipping a light switch, controlling whether genes in a cell are active. When a gene is turned on, the production of proteins or other substances is promoted; when ...

Add Yahoo as a preferred source to see more of our stories on Google. CRISPR Gene Edit Cuts Cholesterol 50% In New Trial Image by Canva A small but promising study using a type of gene-editing ...

Researchers have developed a technology that delivers RNA to damaged neurons and stimulates regrowth - paving the way for potential treatments for neurodegenerative diseases like ALS and spinal ...

The global CRISPR technology market is anticipated to grow at a robust compound annual growth rate of approximately 16% over the next five years. This rapid expansion is driven by continuous ...

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital through a new convertible debt offering. The gene-editing firm said it intends to ...

The coronavirus disease 2019 (COVID-19) pandemic was one of the most serious public health calamities in the last decade, causing global morbidity and mortality in the millions. The emergence of ...

When a neuron in our body gets damaged, segments of RNA produce proteins that can help repair the injury. But in neurological disorders such as ALS and spinal muscular atrophy, or following spinal ...

Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.